Test Your Knowledge on HIV: ART and Weight Gain
Maile Young Karris, MD
Codirector, San Diego Center for AIDS Research Clinical Investigations Core
Department of Medicine
Divisions of Infectious Diseases & Global Public Health and Geriatrics & Gerontology
University of California San Diego
San Diego, California
Young Karis M. Test your knowledge on HIV: ART and weight gain. Consultant360. Published online July 28, 2021.
A 72-year-old woman recently relocated to be closer to her family and presented to your clinic to establish HIV care. Her medical history is significant for insomnia, depression, type 2 diabetes, and chronic hepatitis B virus.
She reported 100% adherence to her antiretroviral regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). Since starting her initial HIV regimen shortly after diagnosis (10 years ago), her HIV has been undetectable, and she has maintained a CD4 T-cell count of more than 500 cells/mL.
She also reported an 8.16-kg weight gain (body mass index, 32 kg/m2) since her previous doctor had switched her from efavirenz/emtricitabine/tenofovir disoproxil (EFV/F/TDF) 2 years ago. She is considering taking a break from her current antiretroviral therapy (ART) to lose some of the weight.
Answer and discussion on next page.